ArticleBMC cancer2016
Long-term survival and BRCA status in male breast cancer: a retrospective single-center analysis.
Article in BMC cancer, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed.
- Male Breast Cancer: An Analysis of Clinicopathological Features, Treatment Patterns, and Survival Outcomes over 10 Years from a Tertiary Center.Journal of clinical medicine · 2026Article
- From lung to breast: a rare case of metastatic lung adenocarcinoma presenting as a breast lump in a male patient.Journal of surgical case reports · 2025Article
- HER2 expression and pathway status in male breast cancer patients: results of an integrated analysis among 6,150 patients.Scientific reports · 2025Article
- Ki67 Expression and Its Association With Clinicopathological Factors and Intrinsic Subtypes of Male Breast Cancer in Uganda: A Cross-sectional Study.Breast cancer : basic and clinical research · 2025Article
- Gender-Specific Genetic Predisposition to Breast Cancer:Cancers · 2024Review
- Peptide-Based Vaccine against Breast Cancer: Recent Advances and Prospects.Pharmaceuticals (Basel, Switzerland) · 2023Review
- Comparison of Clinical, Pathological, and Prognostic Features inEuropean journal of breast health · 2022Article
- Analysis of the Clinical Advancements forCancers · 2022Review
- Review
- Profile of Male Breast Cancer in Makkah Region of Saudi Arabia: A 4-Year Retrospective Analysis of Radiology and Histopathology.International journal of breast cancer · 2022Article
- Care of men with cancer-predisposingBMJ (Clinical research ed.) · 2021Article
- Cancer Spectrum, Family History of Cancer and Overall Survival in Men with GermlineJournal of personalized medicine · 2021Article
- Male Breast Cancer: Clinical, Demographical, and Pathological Features in a Cohort of 41 Patients.Cureus · 2021Article
- Genetic Landscape of Male Breast Cancer.Cancers · 2021Review
- Male and female breast cancer: the two faces of the same genetic susceptibility coin.Breast cancer research and treatment · 2021Article
- Management of patients with BRCA mutation from the point of view of a breast surgeon.Annals of medicine and surgery (2012) · 2021Review
- Male Breast Cancer: Surgical and Genetic Features and a Multidisciplinary Management Strategy.Breast care (Basel, Switzerland) · 2020Article
- Breast Metastasis From Castrate-Resistant Prostatic Adenocarcinoma Mimicking as a Second Primary: A Case Report.World journal of oncology · 2020Article
- Male breast cancer: Specific biological characteristics and survival in a Portuguese cohort.Molecular and clinical oncology · 2019Article
- Diagnostic and prognostic value of 18F-FDG PET/CT imaging in suspected recurrence of male breast cancer.Nuclear medicine communications · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMale breast cancer (MBC) is rare. Given the paucity of randomized trials, treatment is generally extrapolated from female breast cancer guidelines.
methodsThis is a retrospective analysis of all male patients presenting with MBC at the Department of Oncology at University Federico II of Naples between January 1989 and January 2014. We recorded the following data: baseline characteristics (age, height, weight, body mass index, risk factors, family history), tumor characteristics (side affected, stage, histotype, hormonal and HER2 status, and Ki-67 expression), treatment (type of surgery, chemotherapy, endocrine therapy, and/or radiotherapy), BRCA1/2 mutation status (if available), other tumors, and long-term survival.
resultsForty-seven patients were analyzed. Median age was 62.0 [55.0-72.0]. Among risk factors, obesity and family history of breast cancer were associated with 21 % and 30 % of MBC cases, respectively. The majority of tumors were diagnosed at an early stage: stage I (34.0 %) and stage II (44.7 %). Infiltrating ductal carcinoma was the most frequent histologic subtype (95.8 %). Hormone receptors were generally positive (88.4 % of cases were Estrogen receptor [ER] positive and 81.4 % Progesteron receptor [PgR] positive). Human epidermal growth factor receptor 2 (HER2) was positive in 26.8 % of cases; 7.0 % of MBCs were triple negative. The tumor had high proliferation index (Ki67 ≥ 20 %) in 64.7 %. Surgery was predominantly mastectomy (85.1 %), whereas quadrantectomy was performed in 14.9 % of patients. Adjuvant chemotherapy was administered to 70.7 % of patients, endocrine therapy to 90.2 %, trastuzumab to 16.7 % and radiotherapy to 32.6 %. BRCA status was available for 17 patients: 10 wild-type, 1 BRCA1 carrier, 5 BRCA2 carriers, 1 unknown variant sequence. The overall estimated long-term survival was about 90 % at 5 years, 80 % at 10 years and 70 % at 20 years. Patients carrying a BRCA mutation had a significantly lower survival than patients with wild-type BRCA (p = 0.04).
conclusionsLong-term survival was high in MBC patients referred to our clinical unit. Survival was poorer in BRCA-mutated patients than in patients with wild-type BRCA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.